Table of Contents
ISRN Vascular Medicine
Volume 2013 (2013), Article ID 908108, 7 pages
http://dx.doi.org/10.1155/2013/908108
Research Article

Suppression of Receptor for Advanced Glycation End Products Improves Angiogenic Responses to Ischemia in Diabetic Mouse Hindlimb Ischemia Model

1Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Health System, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Republic of Korea
2Korea Institute of Science and Technology, Hwarangno 14-gil 5, Seongbuk-gu, Seoul 136-791, Republic of Korea
3Yonsei Research Institute of Aging Science, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Republic of Korea
4Severance Biomedical Science Institute, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Republic of Korea

Received 16 June 2013; Accepted 8 July 2013

Academic Editors: P. Schoenhagen, V. K. Sharma, S. Takebayashi, and Y. Tohno

Copyright © 2013 Bo Hyun Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. B. Jude, S. O. Oyibo, N. Chalmers, and A. J. M. Boulton, “Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome,” Diabetes Care, vol. 24, no. 8, pp. 1433–1437, 2001. View at Google Scholar · View at Scopus
  2. A. Rivard, M. Silver, D. Chen et al., “Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF,” American Journal of Pathology, vol. 154, no. 2, pp. 355–363, 1999. View at Google Scholar · View at Scopus
  3. A. Roguin, S. Nitecki, I. Rubinstein et al., “Vascular endothelial growth factor (VEGF) fails to improve blood flow and to promote collateralization in a diabetic mouse ischemic hindlimb model,” Cardiovascular Diabetology, vol. 2, article 18, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. C. J. M. Loomans, E. J. P. de Koning, F. J. T. Staal et al., “Endothelial progenitor cell dysfunction,” Diabetes, vol. 53, no. 1, pp. 195–199, 2004. View at Publisher · View at Google Scholar
  5. M. S. Ruiter, J. M. Van Golde, N. C. Schaper, C. D. Stehouwer, and M. S. Huijberts, “Diabetes impairs arteriogenesis in the peripheral circulation: review of molecular mechanisms,” Clinical Science, vol. 119, no. 6, pp. 225–238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Li, S. Hazarika, D. Xie, A. M. Pippen, C. D. Kontos, and B. H. Annex, “In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia,” Diabetes, vol. 56, no. 3, pp. 656–665, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Jakuš and N. Rietbrock, “Advanced glycation end-products and the progress of diabetic vascular complications,” Physiological Research, vol. 53, no. 2, pp. 131–142, 2004. View at Google Scholar · View at Scopus
  8. T. Shoji, H. Koyama, T. Morioka et al., “Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes,” Diabetes, vol. 55, no. 8, pp. 2245–2255, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. S. F. Yan, R. Ramasamy, and A. M. Schmidt, “The RAGE axis a fundamental mechanism signaling danger to the vulnerable vasculature,” Circulation Research, vol. 106, no. 5, pp. 842–853, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Ramasamy, F. Y. Shi, and A. M. Schmidt, “RAGE: therapeutic target and biomarker of the inflammatory response—The evidence mounts,” Journal of Leukocyte Biology, vol. 86, no. 3, pp. 505–512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. A. M. Schmidt, O. Hori, J. X. C. Jing Xian Chen et al., “Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes,” Journal of Clinical Investigation, vol. 96, no. 3, pp. 1395–1403, 1995. View at Google Scholar · View at Scopus
  12. G. Basta, G. Lazzerini, M. Massaro et al., “Advanced glycation end products activate endothelium through signal-transduction receptor RAGE a mechanism for amplification of inflammatory responses,” Circulation, vol. 105, no. 7, pp. 816–822, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. S.-I. Yamagishi, K. Nakamura, T. Matsui, S. Ueda, K. Fukami, and S. Okuda, “Agent that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications,” Expert Opinion on Investigational Drugs, vol. 17, no. 7, pp. 983–996, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. S.-I. Yamagishi, H. Yonekura, Y. Yamamoto et al., “Advanced glycation end products-driven angiogenesis in vitro: induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor,” Journal of Biological Chemistry, vol. 272, no. 13, pp. 8723–8730, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Biscetti, G. Straface, R. De Cristofaro et al., “High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism,” Diabetes, vol. 59, no. 6, pp. 1496–1505, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. I. J. Goldberg, Y. Hu, H.-L. Noh et al., “Decreased lipoprotein clearance is responsible for increased cholesterol in LDL receptor knockout mice with streptozotocin-induced diabetes,” Diabetes, vol. 57, no. 6, pp. 1674–1682, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Biscetti, G. Straface, V. Arena et al., “Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARγ stimulation,” Cardiovascular Diabetology, vol. 8, article 49, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Kuzuya, S. Satake, S. Ai et al., “Inhibition of angiogenesis on glycated collagen lattices,” Diabetologia, vol. 41, no. 5, pp. 491–499, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Lee, K. H. Lee, H. Park et al., “The effect of soluble RAGE on inhibition of angiotensin II-mediated atherosclerosis in apolipoprotein E deficient mice,” PLoS One, vol. 8, no. 8, Article ID e69669, 2013. View at Publisher · View at Google Scholar
  20. J.-S. Silvestre and B. I. Lévy, “Molecular basis of angiopathy in diabetes mellitus,” Circulation Research, vol. 98, no. 1, pp. 4–6, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Koyama, H. Yamamoto, and Y. Nishizawa, “RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases,” Molecular Medicine, vol. 13, no. 11-12, pp. 625–635, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Tamarat, J.-S. Silvestre, M. Huijberts et al., “Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8555–8560, 2003. View at Publisher · View at Google Scholar · View at Scopus